iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.26
(-2.31%)
SEK 0.26
(-2.31%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.82 Million SEK | 149.93% |
| 2022 | 729 Thousand SEK | 64.93% |
| 2021 | 442 Thousand SEK | -95.04% |
| 2020 | 8.9 Million SEK | -37.86% |
| 2019 | 14.32 Million SEK | 89.25% |
| 2018 | 7.57 Million SEK | 4784.52% |
| 2017 | 155 Thousand SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | -100.0% |
| 2013 | 5698.00 SEK | -85.43% |
| 2012 | 39.1 Thousand SEK | 48.0% |
| 2011 | 26.41 Thousand SEK | 604.51% |
| 2010 | 3750.00 SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 2.03 Million SEK | 1108.93% |
| 2024 Q1 | 3.41 Million SEK | 402.21% |
| 2024 Q2 | 168 Thousand SEK | -95.07% |
| 2023 Q1 | 228 Thousand SEK | 17.53% |
| 2023 Q3 | 512 Thousand SEK | 27.05% |
| 2023 Q2 | 403 Thousand SEK | 76.75% |
| 2023 Q4 | 679 Thousand SEK | 32.62% |
| 2023 FY | 1.82 Million SEK | 149.93% |
| 2022 Q2 | 84 Thousand SEK | -77.66% |
| 2022 FY | 729 Thousand SEK | 64.93% |
| 2022 Q3 | 75 Thousand SEK | -10.71% |
| 2022 Q1 | 376 Thousand SEK | 70.91% |
| 2022 Q4 | 194 Thousand SEK | 158.67% |
| 2021 Q2 | 12 Thousand SEK | -93.02% |
| 2021 Q4 | 220 Thousand SEK | 478.95% |
| 2021 Q1 | 172 Thousand SEK | 104.76% |
| 2021 FY | 442 Thousand SEK | -95.04% |
| 2021 Q3 | 38 Thousand SEK | 216.67% |
| 2020 Q2 | 3.68 Million SEK | -17.06% |
| 2020 Q1 | 4.43 Million SEK | -0.74% |
| 2020 Q4 | 84 Thousand SEK | -88.02% |
| 2020 FY | 8.9 Million SEK | -37.86% |
| 2020 Q3 | 701 Thousand SEK | -80.96% |
| 2019 Q2 | 3.17 Million SEK | -5.12% |
| 2019 FY | 14.32 Million SEK | 89.25% |
| 2019 Q3 | 3.34 Million SEK | 5.46% |
| 2019 Q4 | 4.47 Million SEK | 33.7% |
| 2019 Q1 | 3.34 Million SEK | -31.33% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | 7.57 Million SEK | 4784.52% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q3 | 2.7 Million SEK | 0.0% |
| 2018 Q4 | 4.86 Million SEK | 79.99% |
| 2017 Q2 | 1000.00 SEK | -75.51% |
| 2017 Q3 | 6.00 SEK | -99.4% |
| 2017 Q4 | 150.19 Thousand SEK | 2503200.0% |
| 2017 FY | 155 Thousand SEK | 0.0% |
| 2017 Q1 | 4083.00 SEK | -99.29% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 575.73 Thousand SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | -100.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q2 | 532.25 Thousand SEK | 0.0% |
| 2014 Q1 | - SEK | 100.0% |
| 2014 Q3 | - SEK | -100.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 FY | 5698.00 SEK | -85.43% |
| 2013 Q4 | -2.00 SEK | 0.0% |
| 2013 Q1 | 5700.00 SEK | -9.51% |
| 2013 Q2 | - SEK | -100.0% |
| 2012 Q2 | 9899.00 SEK | -30.3% |
| 2012 FY | 39.1 Thousand SEK | 48.0% |
| 2012 Q1 | 14.2 Thousand SEK | 0.0% |
| 2012 Q4 | 6299.00 SEK | -27.6% |
| 2012 Q3 | 8700.00 SEK | -12.11% |
| 2011 FY | 26.41 Thousand SEK | 604.51% |
| 2010 FY | 3750.00 SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AddLife AB (publ) | 9.68 Billion SEK | 99.981% |
| Biotage AB (publ) | 1.86 Billion SEK | 99.902% |
| Bonesupport Holding AB (publ) | 591.07 Million SEK | 99.692% |
| Doxa AB (publ) | 9.9 Million SEK | 81.596% |
| Elekta AB (publ) | 18.11 Billion SEK | 99.99% |
| Ortivus AB (publ) | 84.08 Million SEK | 97.833% |
| Ortivus AB (publ) | 84.08 Million SEK | 97.833% |
| Q-linea AB (publ) | 4.44 Million SEK | 58.964% |
| S2Medical AB (publ) | 6.97 Million SEK | 73.864% |
| Synsam AB (publ) | 5.9 Billion SEK | 99.969% |